Mylan NV (MYL)

MYL (NASDAQ:Drugs) EQUITY
$39.59
neg -0.76
-1.88%
Today's Range: 39.50 - 40.43 | MYL Avg Daily Volume: 5,847,000
Last Update: 03/30/17 - 4:00 PM EDT
Volume: 7,330,618
YTD Performance: 5.77%
Open: $40.21
Previous Close: $40.35
52 Week Range: $37.59 - $67.34
Oustanding Shares: 535,496,988
Market Cap: 22,340,934,339
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 7 7 7
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.91 1.83 1.83 1.83
Latest Dividend: 0.00
Latest Dividend Yield: 0.54%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 45.35
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
45.35 24.50 30.50
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.95% -14.17% -17.37%
GROWTH 12 Mo 3 Yr CAGR
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
EBITDA 2.40B
Revenue 9.43B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.96 $1.27 $5.30 $5.75
Number of Analysts 5 5 7 7
High Estimate $1.12 $1.36 $5.50 $6.04
Low Estimate $0.90 $1.19 $5.15 $5.60
Prior Year $0.76 $1.16 $4.89 $5.30
Growth Rate (Year over Year) 26.58% 9.48% 8.47% 8.38%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Drug companies are the latest targets/beneficiaries.
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
Prices look set to test key resistance, and this time should see a breakout to the upside.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
Bearish
Jan 05, 2017 | 7:26 AM EST
MYL was downgraded to Neutral, Citigroup said. $44 price target. Valuation call, as estimates are below consensus.
Even among the losers, buys are scarce.
If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
The sector excelled right after the election, but lately has been sitting this rally out.

Columnist Conversations

The DJIA has been making lows at a fairly regular interval of 101 days. The cycle tools overlaid on the daily ...
this stock continues to move well, momentum is strong. BOUGHT JACK MAY 100 CALL AT 5.25
I have a special guest joining me today, legendary technician Marc Chaikin comes aboard tonight, talking about...
View Chart »  View in New Window » To fail or not to fail is the question.  The video I d...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.